Neurocrine Biosciences, Inc.
NASDAQ:NBIXBiotechnology
-$0.71 today
- Market cap
- $16.48B
- Beta
- 0.40
- P/E (TTM)
- 23.8
- EPS (TTM)
- $6.65
Volume 1.60M
Average 1.18M
NBIX Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Neurocrine Biosciences, Inc.NASDAQ: NBIX
Net Margin · Q3 FY2026 · quarter ended Sep 2026
Net margin narrows to 18.4%
Net margin was 18.4% in Q3 FY2026, down 8.0 pp from a year earlier. On a trailing-twelve-month basis it was 19.0%, up 3.0 pp year over year. Over 3 fiscal years it widened by 6.4 pp.
Context
- Net margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 18 analysts of 18.8% for the fiscal year ending Dec 2026, up from 16.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- 18.4%+3.3 pp QoQ
- Last fiscal yearDec 2025
- 16.7%+2.2 pp YoY
- LTMSep 2026
- 19.0%+3.0 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -8.0 pp | +0.8 pp | +8.8 pp |
| 1 year | +2.2 pp | +2.1 pp | -0.2 pp |
| 3 years | +6.4 pp | +16.0 pp | +9.6 pp |
| 5 years | +8.6 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 16.7%
- Year-over-year change
- +2.2pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.7% | +2.2pp |
| FY2024 | 2024-12-31 | 14.5% | +1.3pp |
| FY2023 | 2023-12-31 | 13.2% | +2.9pp |
| FY2022 | 2022-12-31 | 10.4% | +2.5pp |
| FY2021 | 2021-12-31 | 7.9% | — |
Net Margin vs competitors
How NBIX compares with its peers on the latest reported figures
- NBIX's LTM Sep 2026 net margin of 19.0% is the 2nd highest of the 7 companies compared; the peer median is -19.0%.
- Its year-over-year change of +3.0 pp is the 4th highest of 6, against a peer median of +5.2 pp.
- Over three fiscal years its change of +6.4 pp compares with a peer median of -2.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 30.1% | +5.2 pp | +78.2 pp | |
| LTM Sep 2026 | 19.0% | +3.0 pp | +6.4 pp | |
| LTM Sep 2026 | 4.4% | +13.2 pp | -2.2 pp | |
| LTM Jun 2026 | -13.2% | -22.9 pp | -14.5 pp | |
| LTM Jun 2026 | -24.7% | +25.2 pp | +345.3 pp | |
| LTM Mar 2026 | -110.0% | -88.0 pp | -104.5 pp | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -536.4% | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | FY2025 | — | — | — |
| Peer median (excluding NBIX) | -19.0% | +5.2 pp | -2.2 pp | |
Competitors are the stored peer set for NBIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.13B | 1.49B | 1.89B | 2.36B | 2.86B |
| Cost of Revenue | 14.3M | 23.2M | 39.7M | 34M | 52.1M |
| Gross Profit | 1.12B | 1.47B | 1.85B | 2.32B | 2.81B |
| Gross Margin | 98.7% | 98.4% | 97.9% | 98.6% | 98.2% |
| Research & Development | 328.1M | 463.8M | 565M | 731.1M | 1.02B |
| Selling, General & Admin | 583.3M | 752.7M | 887.6M | 1.01B | 1.16B |
| Operating Expenses | 1.02B | 1.22B | 1.6B | 1.75B | 2.19B |
| Depreciation & Amortization | 10.9M | 15.6M | 21.3M | 27.1M | 30.1M |
| EBITDA | 138.1M | 236.6M | 416.1M | 639.7M | 666.6M |
| EBITDA Margin | 12.2% | 15.9% | 22.0% | 27.2% | 23.3% |
| Operating Income | 102.5M | 249M | 250.9M | 570.5M | 619.1M |
| Operating Margin | 9.0% | 16.7% | 13.3% | 24.2% | 21.6% |
| Interest Income | 0 | 11.2M | 0 | 91M | 90.3M |
| Interest Expense | 25.8M | 7.1M | 4.6M | 126.6M | 0 |
| Other Income / Expenses | (1.1M) | (35.1M) | 81.2M | (84.5M) | 86.3M |
| Income Before Tax | 101.4M | 213.9M | 332.1M | 486M | 705.4M |
| Pre-Tax Margin | 8.9% | 14.4% | 17.6% | 20.6% | 24.7% |
| Income Tax Expense | 11.8M | 59.4M | 82.4M | 144.7M | 226.8M |
| Net Income | 89.6M | 154.5M | 249.7M | 341.3M | 478.6M |
| Net Margin | 7.9% | 10.4% | 13.2% | 14.5% | 16.7% |
| EPS (Basic) | 0.95 | 1.61 | 2.56 | 3.40 | 4.81 |
| EPS (Diluted) | 0.92 | 1.56 | 2.47 | 3.29 | 4.67 |
| Weighted Avg Shares | 94.6M | 95.8M | 97.7M | 100.4M | 99.5M |
| Weighted Avg Shares (Diluted) | 97.9M | 98.9M | 101M | 103.7M | 102.5M |
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
Intrinsic Alpha fair value
Locked
Current Price
$162.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.